Antibody based therapies in Hodgkin lymphoma

Vivek S Radhakrishnan; Jemma Longley; Peter W M Johnson

doi:10.1016/j.ctrv.2023.102647

Antibody based therapies in Hodgkin lymphoma

Cancer Treat Rev. 2024 Jan:122:102647. doi: 10.1016/j.ctrv.2023.102647. Epub 2023 Oct 28.

Authors

Vivek S Radhakrishnan¹, Jemma Longley², Peter W M Johnson³

Affiliations

¹ Department of Medical Oncology, University Hospital Southampton NHS Trust, Southampton, UK.
² Department of Medical Oncology, University Hospital Southampton NHS Trust, Southampton, UK; School of Cancer Sciences, University of Southampton, Southampton, UK.
³ Department of Medical Oncology, University Hospital Southampton NHS Trust, Southampton, UK; School of Cancer Sciences, University of Southampton, Southampton, UK. Electronic address: johnsonp@soton.ac.uk.

PMID: 37988820
DOI: 10.1016/j.ctrv.2023.102647

Abstract

Multimodality treatment approaches, with systemic therapies at their core, have made Hodgkin Lymphoma a highly curable cancer. Unmet needs remain. Resistance to therapy manifested by refractory and relapsed disease, and treatment related short- and long-term morbidity are the key challenges. Patient outcomes have improved in the recent past with the advent of novel therapies and are borne out of a better understanding of the disease biology and translational medicine. Antibody based therapies, more broadly immunotherapies, are leading the change in the way we treat this disease. This review looks at the tumor antigen-directed immunotherapies, and immune checkpoint inhibitors that are attempting to overcome the unmet challenges.

Keywords: Antibody-drug conjugate; Cellular therapy; Checkpoint inhibitor; Hodgkin Lymphoma; Immunotherapy.

Publication types

Review

MeSH terms

Combined Modality Therapy
Hodgkin Disease* / drug therapy
Humans
Immunotherapy